9 research outputs found
Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
Full text linkSingle-Dose Pharmacokinetics and Safety Pharmacodynamics of Formoterol Delivered by Two Different Dry Powder Inhalers
No full textDetermination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach
No full textAdjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial
No full textProposal for an individualized dietary strategy in patients with very long-chain acyl-CoA dehydrogenase deficiency
No full text
SEOM clinical guidelines in early stage breast cancer (2018)
No full textBreast cancer is the most common cancer in women in our country and it is usually diagnosed in the early and potentially curable stages. Nevertheless, around 20-30% of patients will relapse despite appropriate locoregional and systemic therapies. A better knowledge of this disease is improving our ability to select the most appropriate therapy for each patient with a recent diagnosis of an early stage breast cancer, minimizing unnecessary toxicities and improving long-term efficacy
